

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known Application Number: <u>To be assigned 16/670,668</u> Filing Date: <u>September 25, 2003</u> First Named Inventor: <u>Richard H. INGRAHAM</u> Art Unit: <u>1626</u> Examiner Name: <u>Ramsay R. Gr. Shameen</u> Attorney Docket Number: <u>9/213-1-C1</u>		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
GAS		US- 6,348,480	02/19/2002	Kubota, H. et al	
		US- 6,506,747	01/14/2003	Betageri, R. et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 99 51580 A1	10/14/1999	Abbott Lab.		
		WO 00 23060 A2	04/27/2000	BI Pharm., Inc.		

Examiner Signature		Date Considered	<u>6/23/04</u>
-----------------------	--	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08b (08-03)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete If Known

Application Number

10/670,668

Filing Date

September 25, 2003

First Named Inventor

Ingraham, R.H. et al

Art Unit

1626

Examiner Name

Shameem, G.M.

Attorney Docket Number

9/213-1-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS		James M. TREVILLYAN, et al; Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds, Journal of Biological Chemistry, Vol. 276, No. 51 pp. 48118-48126, 2001	
		Christof ZITT, et al; Potent Inhibition of Ca ²⁺ Release-activated Ca ²⁺ Channels and T-lymphocyte Activation by the Pyrazole Derivative BTP ² , Journal of Biological Chemistry, Vol. 279, No. 13, Issue of March 26, pp12427-12437, 2004	
		Jun ISHIKAWA, et al; A Pyrazole Derivative, YM-58483, Potently Inhibits Store-Operated Sustained Ca ²⁺ Influx and IL-2 Production in T Lymphocytes, The Journal of Immunology pp. 4441-4449	
		Steven DJURIC, et al; 3-5 Bis(trifluoromethyl)pyrazoles: A Novel Class of NFAT Transcription Factor Regulator, Journal of Med. Chem. 2000, 43, 2975-2981	
AS		Yung-Wu CHEN, et al; TH1 and TH2 cytokine inhibition by 3-5 Bis(trifluoromethyl) pyrazoles, a novel class of immunomodulators, Cellular Immunology 220 (2002) 134-142	

Examiner Signature		Date Considered	6/23/04
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.